About
All Posts
Partner
Logo
Login
Subscribe
Logo
  • Home
  • Posts
  • Eli Lilly strikes $2.75B deal with Insilico for AI-developed drugs

Mar 30, 2026

Eli Lilly strikes $2.75B deal with Insilico for AI-developed drugs

Bay Area Times
Bay Area Times
Eli Lilly strikes $2.75B deal with Insilico for AI-developed drugs

Brought to you by:

Top stories today:

  1. Eli Lilly strikes $2.75B deal with Insilico for AI-developed drugs
  2. Meta to unveil Ray-Ban smart glasses for prescription wearers this week
  3. xAI loses last cofounder Ross Nordeen, ending Elon’s founding team
  4. Physical Intelligence said to seek $1B round at $11B+ valuation
  5. Kalshi secures margin trading license to attract institutional investors
  6. Meta’s Avocado seen testing multiple AI variants, including 9B model

Follow us on X | Instagram | Advertise

0. Data and calendar

All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).

All times are ET.

Listen to our AI-generated podcast summarizing today’s newsletter (beware of hallucinations):

1. Eli Lilly strikes $2.75B deal with Insilico for AI-developed drugs

Insilico Medicine shares closed +3% Mon. after rising as much as 15%, their strongest intraday rally in ~2 months:

Google Finance: Insilico Medicine stock.

  • Insilico will receive $15M upfront, with the rest tied to regulatory and commercial milestones.

  • The deal also includes royalties on future sales.

  • Insilico has developed at least 28 drugs using GenAI, ~50% of them are already in clinical stages, CEO Alex Zhavoronkov said.

  • 2023: Eli Lilly and Insilico signed an AI software licensing deal.

  • Insilico develops AI outside China but conducts early preclinical work there.

2. Meet the all-new Slackbot, your personal AI agent for work*

Slack.

  • Watch the on-demand webinar to see how Slackbot lives in the flow of work, already understanding your conversations, files, and people—delivering answers and actions that are relevant and personalized to you.

  • Learn from real Slack customers, like Engine and Asymbl, as they share how Slackbot finds answers, analyzes documents, schedules meetings, creates content, and orchestrates specialized agents to execute complex workflows.

  • See contextual intelligence in action as Slackbot moves work forward by respecting your permissions and working with the tools you trust.

Watch now

*Sponsored.

3. Meta said to launch Ray-Ban smart glasses for prescription wearers this week

Meta.

  • Rectangular and rounded styles are expected.

  • Codenamed Scriber and Blazer, they are not next-gen Meta smart glasses.

  • ā€œ[B]illions of people wear glasses or contacts,ā€ Mark Zuckerberg said, hinting at a broader push into prescription wearers.

4. xAI loses last cofounder Ross Nordeen, ending Elon’s founding team

Nordeen has also lost the badge on X that identifies him as an xAI employee:

X: Ross.

Subscribe to keep reading

This content is free, but you must be subscribed to Bay Area Times to continue reading.

Already a subscriber?Sign in.Not now

Keep reading

Nov 9, 2026

NVIDIA board launches spy plot probe as Jensen Huang discloses romantic relationship

NVIDIA board launches spy plot probe as Jensen Huang discloses romantic relationship

Nov 6, 2026

OpenAI’s GPT-6 Cyber debuts with better vulnerability detection, stronger performance

OpenAI’s GPT-6 Cyber debuts with better vulnerability detection, stronger performance

Nov 5, 2026

Data center stocks tumble on AI slowdown fears after Democratic sweep

Data center stocks tumble on AI slowdown fears after Democratic sweep

Nov 4, 2026

Google faces backlash over plan to block Search at schools rejecting AI

Google faces backlash over plan to block Search at schools rejecting AI

Subscribe

Your morning briefing, free forever.

Get the latest news, resources, and more delivered straight to your inbox everyday.

The visual daily newsletter on business and tech. Analyzing the news with 1 visual per story. Join our 250,000+ subscribers here.

Copyright Ā© 2026 Bay Area Times.

BAT

Archive Posts

Partner

Company

About Us

Legal

Privacy Policy

Terms of Service